Literature DB >> 17552062

The future of damage assessment in vasculitis.

Philip Seo1, Raashid A Luqmani, Oliver Flossmann, Bernhard Hellmich, Karen Herlyn, Gary S Hoffman, David Jayne, Cees G M Kallenberg, Carol A Langford, Alfred Mahr, Eric L Matteson, Chetan B Mukhtyar, Tuhina Neogi, Abraham Rutgers, Ulrich Specks, John H Stone, Steven R Ytterberg, Peter A Merkel.   

Abstract

Damage denotes the aspects of chronic disease that do not reverse with therapy. This concept is particularly important for the primary systemic vasculitides, since the careful differentiation between activity and damage may help avoid unnecessary exposure to cytotoxic medications. Damage significantly influences both longterm prognosis and quality of life. Because the primary systemic vasculitides have diverse manifestations, the use of a damage assessment instrument is crucial to ensure reproducibility. The Vasculitis Damage Index (VDI) is the only validated measure for damage assessment in vasculitis. Use of the VDI in recent clinical trials has shown that it may not adequately determine the full spectrum of damage experienced by patients with vasculitis of small- and medium-size vessels. We propose reexamining the way in which damage is assessed, focusing on vasculitides of small- and medium-size vessels, and outline an initiative to create a substantially revised and improved damage assessment instrument using data-driven approaches. This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides.

Entities:  

Mesh:

Year:  2007        PMID: 17552062

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

1.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

2.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

3.  The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Haner Direskeneli; Karen Herlyn; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Raashid A Luqmani
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

4.  Long-term damage to the ENT system in Wegener's granulomatosis.

Authors:  Marcos Martinez Del Pero; Michael Walsh; Raashid Luqmani; Oliver Flossmann; Chetan Mukhtyar; Piyush Jani; Niels Rasmussen; David Jayne
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-18       Impact factor: 2.503

5.  Vasculitis: lessons learned.

Authors:  Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

6.  Current status of outcome measure development in vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Christina Cornell; Haner Direskeneli; Don Gebhart; Gulen Hatemi; Raashid Luqmani; Eric L Matteson; Nataliya Milman; Joanna Robson; Philip Seo; Gunnar Tomasson
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

7.  Assessment of damage in vasculitis: expert ratings of damage.

Authors:  Philip Seo; David Jayne; Raashid Luqmani; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2009-05-19       Impact factor: 7.580

Review 8.  Damage assessment in ANCA-associated vasculitis.

Authors:  Kuljeet Bhamra; Raashid Luqmani
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

9.  Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

Authors:  Peter A Merkel; Karen Herlyn; Alfred D Mahr; Tuhina Neogi; Philip Seo; Michael Walsh; Maarten Boers; Raashid Luqmani
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

Review 10.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.